Gene · 9475
ROCK2: Rho associated coiled-coil containing protein kinase 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ROCK2: Rho associated coiled-coil containing protein kinase 2. Genes, record 9475. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9475
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O75116 | Rho-associated protein kinase 2 | 1,388 | 23 | Ensembl, GeneID, HGNC |
Source UniProt
Patents48
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61828 | O75116 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5147 | O75116 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 4745 | O75116 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 4745 | O75116 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5147 | O75116 | Espacenet |
| EP 4491229 A2 | 2025-01-15 | 233 | O75116 | Espacenet |
| WO 2024230934 A1 | 2024-11-14 | 358 | O75116 | Espacenet |
| JP 2024510010 A | 2024-03-05 | 219 | O75116 | Espacenet |
| US 11920164 B2 | 2024-03-05 | 51 | O75116 | Espacenet |
| WO 2022195543 A | 2022-09-22 | 219 | O75116 | Espacenet |
1 to 10 of 48
See all 48 patentsDrugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMA0076 | CHEMBL3545073 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| AT-13148 | CHEMBL3544960 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| BELUMOSUDIL | CHEMBL2005186 | Rho-associated protein kinase 2 inhibitor | INHIBITOR | ChEMBL |
| BELUMOSUDIL | CHEMBL2005186 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| BELUMOSUDIL MESYLATE | CHEMBL4802130 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| DE-104 | CHEMBL3545153 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| FASUDIL | CHEMBL38380 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| NETARSUDIL | CHEMBL4594250 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| NETARSUDIL DIMESYLATE | CHEMBL4594251 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
| RIPASUDIL | CHEMBL3426621 | Rho-associated protein kinase inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials87
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07588152 | NETARSUDIL | PHASE4 | ClinicalTrials.gov | |
| NCT07484113 | BELUMOSUDIL | PHASE1 | ClinicalTrials.gov | |
| NCT07325240 | NETARSUDIL | PHASE4 | ClinicalTrials.gov | |
| NCT07135973 | BELUMOSUDIL | PHASE4 | ClinicalTrials.gov | |
| NCT07116031 | BELUMOSUDIL | PHASE2 | ClinicalTrials.gov | |
| NCT07082816 | NETARSUDIL | PHASE3 | ClinicalTrials.gov | |
| NCT07048886 | NETARSUDIL | PHASE4 | ClinicalTrials.gov | |
| NCT06969586 | NETARSUDIL | ClinicalTrials.gov | ||
| NCT06960629 | NETARSUDIL | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06883123 | NETARSUDIL DIMESYLATE | PHASE4 | ClinicalTrials.gov |
1 to 10 of 87
See all 87 trialsNIH grants1,972
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ROCK2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 11 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 9 | 2025 |
| R01AG061800 | Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease | 8 | 2025 |
| R01HL118979 | Enhancing Treg Therapeutic Efficacy in GVHD | 7 | 2025 |
| T32NS061788 | UAB Research Training Program in Neurobiology of Cognition and Cognitive Disorders | 7 | 2025 |
| P30CA056036 | Translational Research in Cancer | 6 | 2025 |
| P01HL158505 | Mechanisms and Therapy of Chronic Graft-vs.-Host Disease | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| R37AI034495 | In Vivo Prevention of Murine GVHD | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
1 to 10 of 1,972Source NIH's project files
See all 1,972 nih grantsPapers3,801
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Bacopa monnieri attenuates Alzheimer's pathology by modulating RNA metabolism, cellular stress responses, and Rho GTPase signaling: Phosphoproteomic insights from a cellular model of Alzheimer's disease. | Neurochem Int | 2026 | 42810623 | PubTator, text mining | PubMed |
| Phosphoproteomic Data Integration Reveals Paralog-Specific Co-Regulatory Networks of Rho-Associated Kinases ROCK1 and ROCK2. | Int J Mol Sci | 2026 | 42794553 | PubTator, text mining | PubMed |
| RhoA in postnatal spinal motoneuron is essential for peripheral myelination. | Commun Biol | 2026 | 42760283 | PubTator, text mining | PubMed |
| Neuroinflammation in postoperative cognitive dysfunction: the multi-target potential of esketamine in modulating microglial responses and synaptic integrity. | Front Mol Neurosci | 2026 | 42751135 | PubTator, text mining | PubMed |
| Safety and Efficacy of Belumosudil for Steroid-Resistant Chronic-Graft-Versus-Host Disease: A Systematic Review. | Indian J Hematol Blood Transfus | 2026 | 42712726 | PubTator, text mining | PubMed |
| From metabolic antagonism to homeostatic restoration: rewiring hepatic stellate cell bioenergetics for liver fibrosis reversal. | Front Med (Lausanne) | 2026 | 42708043 | PubTator, text mining | PubMed |
| Canonical and non-canonical STAT3 pathways in epilepsy: Mechanistic insights and translational challenges. | Life Sci | 2026 | 42679992 | PubTator, text mining | PubMed |
| Belumosudil Demonstrates Steroid-Sparing, Safety, and Efficacy in Pediatric Chronic Graft-Versus-Host Disease. | Transplant Cell Ther | 2026 | 42665020 | PubTator, text mining | PubMed |
| [Retracted] miR-185-5p targets ROCK2 and inhibits cell migration and invasion of hepatocellular carcinoma. | Oncol Lett | 2026 | 42639424 | PubTator, text mining | PubMed |
| Structure-based discovery of novel ROCK2 inhibitors using integrated virtual screening, molecular dynamics, metadynamics and absolute binding free energy calculations. | In Silico Pharmacol | 2026 | 42614366 | PubTator, text mining | PubMed |
1 to 10 of 3,801
See all 3,801 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9475
GET https://conductscience.org/api/genes/v1/9475/patents?page=2